First-of-its-Kind Multi-Modal AI Platform Combines Advanced Behavioral Analysis with Claude AI to Accelerate Traumatic Brain ...
Well, after the treatment for transthyretin cardiac amyloidosis has started, our main focus is to look at the progression of ...
First safety-and-efficacy readout from selective PARP1 inhibitor EIK1003-001 New clinical trial collaboration and supply agreement with Merck First patient dosed in Phase 1/2 study of CNS-penetrant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback